Mechanisms of Resistance to Targeted Therapies in Chronic Lymphocytic Leukemia.

about

Targeting the Adenosinergic Axis in Chronic Lymphocytic Leukemia: A Way to Disrupt the Tumor Niche?

P2860

Q52323624-3AF63CD3-0150-45F9-B6FD-1EB31837C055

P2860

Mechanisms of Resistance to Targeted Therapies in Chronic Lymphocytic Leukemia.

Item

http://www.wikidata.org/entity/Q39169789

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Mechanisms of Resistance to Targeted Therapies in Chronic Lymphocytic Leukemia.

@en

Mechanisms of Resistance to Targeted Therapies in Chronic Lymphocytic Leukemia.

@nl

type

Item

label

Mechanisms of Resistance to Targeted Therapies in Chronic Lymphocytic Leukemia.

@en

Mechanisms of Resistance to Targeted Therapies in Chronic Lymphocytic Leukemia.

@nl

prefLabel

Mechanisms of Resistance to Targeted Therapies in Chronic Lymphocytic Leukemia.

@en

Mechanisms of Resistance to Targeted Therapies in Chronic Lymphocytic Leukemia.

@nl

P1476

Mechanisms of Resistance to Targeted Therapies in Chronic Lymphocytic Leukemia.

@en

P2093

Francesca Arruga

http://www.w3.org/2001/XMLSchema#string

Silvia Deaglio

http://www.w3.org/2001/XMLSchema#string

P2860

Hallmarks of Cancer: The Next Generation

Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

Targeted therapies in CLL: mechanisms of resistance and strategies for management

Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up.

TP53 mutation and survival in chronic lymphocytic leukemia.

Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation.

SF3B1 mutations in chronic lymphocytic leukemia.

Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib

P31

scholarly article

P356

10.1007/164_2017_12

http://www.w3.org/2001/XMLSchema#string

P577

2017-03-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28275912

http://www.w3.org/2001/XMLSchema#string

P921

lymphocyte

Mechanisms of Resistance to Targeted Therapies in Chronic Lymphocytic Leukemia.

about

P2860

P2860

Mechanisms of Resistance to Targeted Therapies in Chronic Lymphocytic Leukemia.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P31

P356

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P31

P356

P577

P698

P921